Genetic testing and precision medicine company Myriad Genetics has expanded access to SneakPeek, an at-home early foetal sex DNA test with the retail launch in the US.
The retail test kit features the patented SneakPeek Snap device, which collects a nearly painless blood sample from the user’s upper arm with the press of a button.
This sample is then sent to the SneakPeek lab in a prepaid envelope. Results are delivered as soon as the same day the sample is received, sent via celebratory text and email.
The latest expansion will make prenatal testing more accessible for parents. It will be available over the counter in 8,800+ retail locations nationwide.
It will be available on Walmart shelves, giving expectant parents the ability to learn their baby’s gender as early as six weeks into pregnancy. It will also be available at Walgreens and CVS stores.
Myriad Genetics expands SneakPeek’s retail presence as part of a broader rebrand, including new packaging and a website focused on parental bonding, scheduled for 2025.
According to the genetic testing firm, the test offers over 99% accuracy as early as six weeks.
Since 2015, SneakPeek has provided an easy, non-invasive way for expectant families to learn their baby’s gender.
In 2022, the precision medicine company acquired SneakPeek’s parent company, Gateway Genomics, for $67.5m in cash to expand consumer access to the at-home foetal sex test via retail partnerships.
Myriad Genetics women’s health president Melissa Gonzales said: “Our commitment to supporting new families is about providing trusted, affordable and accessible solutions that empower expectant parents with information when and where they want it.
“By expanding access of the SneakPeek test through national retail partners, we’re making it easier for more families to experience the meaningful moment of gender discovery and plan and prepare for parenthood.”
Myriad Genetics offers genetic tests that assess disease risk, track disease progression, and guide treatment decisions across various medical specialities.
Other products in Myriad Genetics’ women’s health line include the Prequel non-invasive prenatal screen, Foresight carrier screening, and the MyRisk Hereditary Cancer Test with RiskScore, available for all ancestries.
Last month, Myriad Genetics and Ultima Genomics partnered to assess the use of the latter’s UG 100 sequencing platform and its ppmSeq technology.
